Clinton Enos
YOU?
Author Swipe
View article: Assessment of Primary Malignancy Risk after Initiation of Biologic Therapy in Patients with Psoriasis
Assessment of Primary Malignancy Risk after Initiation of Biologic Therapy in Patients with Psoriasis Open
Limited evidence exists regarding the long-term oncologic safety of biologic therapies, particularly IL-17 inhibitors and IL-23 inhibitors, in the management of psoriasis. This propensity score-matched retrospective cohort study assessed t…
View article: Irritable Bowel Syndrome Risk in Acne Patients: Implications for Dermatologic Care
Irritable Bowel Syndrome Risk in Acne Patients: Implications for Dermatologic Care Open
[Practice points] Clinicians should consider monitoring for early signs of irritable bowel syndrome (IBS) in adult patients with acne to facilitate prompt diagnosis and intervention. Clinicians should remain judicious when prescribing anti…
View article: CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity forCEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells
CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity forCEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells Open
Background: CEACAM5 and CEACAM6 are glycosylphosphatidylinositol (GPI)- linked members of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family, which are frequently upregulated in epithelial cancers where they contri…
View article: The Effects of Cardiometabolic Comorbidities on Biologic Treatment for Psoriasis with Respect to PASI Scores: A Qualitative Systematic Review
The Effects of Cardiometabolic Comorbidities on Biologic Treatment for Psoriasis with Respect to PASI Scores: A Qualitative Systematic Review Open
Relationships between cardiometabolic risk factors and lower frequencies of achieving PASI75/90 exist in current literature. This qualitative systematic review reports evidence of lower PASI75 and PASI90 response rates in the presence of c…
View article: Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities
Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities Open
Background Among psoriasis patients, the presence of metabolic comorbidities associates with poorer response to biologics. How the presence of comorbidity impacts treatment patterns with biologics is not fully understood. Methods Adult pat…
View article: Cardiometabolic multimorbidity is common among patients with psoriasis and is associated with poorer outcomes compared to those without comorbidity
Cardiometabolic multimorbidity is common among patients with psoriasis and is associated with poorer outcomes compared to those without comorbidity Open
Associations between cardiometabolic multimorbidity and response to therapy in psoriasis are unknown. Determine the associations of multimorbidity with response to biologic treatment in psoriasis patients. CorEvitas Psoriasis Registry part…
View article: Geographic Patterns in Psoriasis: An Observational Study of CorEvitas Psoriasis Registry
Geographic Patterns in Psoriasis: An Observational Study of CorEvitas Psoriasis Registry Open
Background: How psoriasis disease characteristics, management, and outcomes each vary across the US is not fully understood. Objective: Assess regional disease characteristics for patients enrolled in CorEvitas Psoriasis Registry, report b…
View article: Regional Variation in DLQI 0/1 within the CorEvitas Psoriasis Registry 6-months following Biologic Initiation
Regional Variation in DLQI 0/1 within the CorEvitas Psoriasis Registry 6-months following Biologic Initiation Open
Background: Patients with psoriasis frequently experience anxiety, depression, and increased psychological distress in association with their disease. Previous work has shown that Dermatology Life Quality Index (DLQI) scores directly assoc…
View article: Supplemental Material from JAAD Original Article Titled: Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6-months: a prospective analysis in the Corrona Psoriasis Registry
Supplemental Material from JAAD Original Article Titled: Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6-months: a prospective analysis in the Corrona Psoriasis Registry Open
This data was collected from patients enrolled in CorEvitas’ Psoriasis Registry from April 2015 through June 2020. Supplemental Table 1: Proportion of patients achieving BSA≤1% and IGA0/1 by drug class and metabolic comorbid disease. Suppl…
View article: Psoriasis Severity, Comorbidities, and Treatment Response Differ among Geographic Regions in the United States
Psoriasis Severity, Comorbidities, and Treatment Response Differ among Geographic Regions in the United States Open
Little is known about how psoriatic disease characteristics and treatment outcomes differ geographically in the United States. Our aim was to explore real-world, geographic variations in the use of biologic classes and outcomes within the …
View article: Sun-protection Behaviors Among Active Members of the United States Lifesaving Association.
Sun-protection Behaviors Among Active Members of the United States Lifesaving Association. Open
BACKGROUND: Ultraviolet radiation exposure is the most prominent modifible risk factor for developing both melanoma and non-melanoma skin cancers. OBJECTIVE: We sought to elucidate sun-protective behaviors among active members of the Unite…
View article: The Role of Neighborhood Characteristics in Late Stage Melanoma Diagnosis among Hispanic Men in California, Texas, and Florida, 1996–2012
The Role of Neighborhood Characteristics in Late Stage Melanoma Diagnosis among Hispanic Men in California, Texas, and Florida, 1996–2012 Open
Background . Hispanics diagnosed with cutaneous melanoma are more likely to present at advanced stages but the reasons for this are unknown. We identify census tracts at high risk for late stage melanoma diagnosis (LSMD) and examine the co…